Dry Eye Syndrome (DED) is a prevalent condition affecting millions worldwide, causing discomfort and potentially impacting vision. Traditional treatments often involve artificial tears or anti-inflammatory drops, but these can have limitations such as short ocular residence time and frequent administration requirements. This has spurred innovation in ophthalmic drug delivery, with a particular focus on leveraging natural compounds like Epigallocatechin Gallate (EGCG).

EGCG, a potent polyphenol found abundantly in green tea, is well-known for its significant anti-inflammatory and antioxidant properties. These characteristics make it a promising candidate for managing DED, which often involves inflammatory processes and oxidative stress on the ocular surface. However, simply applying EGCG in conventional eye drops can limit its therapeutic potential due to rapid clearance from the eye.

To overcome this challenge, researchers and manufacturers are exploring advanced delivery systems. One such innovation involves encapsulating EGCG within biodegradable in situ gelling hydrogels. These advanced formulations, like those developed using gelatin-g-poly(N-isopropylacrylamide) (GN), are designed to be liquid at room temperature but form a gel upon contact with the higher temperature of the eye. This transition ensures the EGCG remains localized on the ocular surface for a longer duration, enabling sustained release of the active compound.

Studies have demonstrated that EGCG-loaded GN hydrogels exhibit excellent biocompatibility with ocular tissues and provide a significantly extended therapeutic effect compared to free EGCG solutions. In animal models of dry eye, these formulations have shown remarkable success in reducing corneal inflammation, mitigating oxidative stress, and improving overall ocular surface health. The sustained release mechanism ensures that therapeutic levels of EGCG are maintained, leading to more effective symptom relief and better management of the underlying causes of DED.

As a leading supplier in China, NINGBO INNO PHARMCHEM CO.,LTD. is at the forefront of developing and providing high-quality ingredients and formulations for the pharmaceutical industry. Our expertise in producing EGCG and formulating it into advanced delivery systems like the GN hydrogel signifies our commitment to advancing eye care solutions. By offering these innovative products, we aim to support researchers and companies in their pursuit of more effective treatments for conditions like Dry Eye Syndrome, ultimately improving patient quality of life. The combination of natural potency and cutting-edge delivery technology marks a new era in ophthalmic therapeutics, and we are proud to be a part of this progress.